首页> 外文期刊>Molecular Systems Design & Engineering >Molecular insights into Mmpl3 lead to the development of novel indole-2-carboxamides as antitubercular agent
【24h】

Molecular insights into Mmpl3 lead to the development of novel indole-2-carboxamides as antitubercular agent

机译:分子洞察Mmpl3导致发展新型indole-2-carboxamides抗结核的代理

获取原文
获取原文并翻译 | 示例
           

摘要

Tuberculosis (TB) is an air-borne infectious disease and is the leading cause of death among all infectious diseases globally. The current treatment regimen for TB is overtly long and patient non-compliance often leads to drug resistant TB resulting in a need to develop new drugs that will act via novel mechanisms. In this research work, we selected mycobacterial membrane protein Large 3 (MmpL3) as the drug target and indole-2-carboximide as our molecule of interest for further designing new molecules. A homology model was prepared for Mycobacterium tuberculosis MmpL3 from the crystal structure of Mycobacterium smegmatis MmpL3. A series of indoles which are known to be MmpL3 inhibitors were docked in the prepared protein and the binding site properties were identified. Based on that, 10 molecules were designed and synthesized and their antitubercular activities were evaluated. We identified four hits among which the highest potency candidate possessed a minimum inhibitory concentration (MIC) of 1.56 mu M at 2 weeks. Finally, molecular dynamics simulation studies were done with 3b and a previously reported MmpL3 inhibitor to understand the intricacies of their binding in real time and to correlate the experimental findings with the simulation data.
机译:结核病是一个空气传播的传染病疾病和死亡的主要原因全球所有传染病。结核病长明显,治疗方案病人不符合通常会导致药物耐药结核病导致需要开发新的药物将通过新的机制。研究工作,我们选择了分枝杆菌膜蛋白质大3 (MmpL3)作为目标和药物indole-2-carboximide作为我们感兴趣的分子为进一步设计新的分子。模型准备结核分枝杆菌MmpL3分枝杆菌的晶体结构smegmatis MmpL3。已知MmpL3抑制剂停靠在了准备蛋白质和结合位点的属性被确定。设计和合成及其抗结核的活动进行评估。点击其中的最高效力的候选人拥有一个最低抑制浓度(MIC) 1.56μM在2周。动力学仿真研究和3 b先前报道MmpL3抑制剂了解错综复杂的绑定实时和相关实验结果与仿真数据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号